Company news
Galderma Group Ag (SIX:GALD) news
Galderma Group Ag news releases on 6ix. Latest, Jul 1, 2025: Galderma Announces Departure of Its Chief Financial Officer
Press releases — page 2
Galderma Announces Departure of Its Chief Financial Officer
July 1, 2025
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
June 25, 2025
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
June 18, 2025
Galderma’s Nemluvio® (nemolizumab) Receives National Institute for Health and Care Excellence (NICE) Recommendation for Moderate-to-severe Atopic Dermatitis in England and Wales
June 12, 2025
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
June 6, 2025
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering
May 28, 2025
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
May 27, 2025
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance
April 24, 2025
Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®
April 17, 2025
Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets
April 15, 2025
AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community
March 20, 2025
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience
March 17, 2025
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond
March 6, 2025
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum
March 3, 2025
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 18, 2025